Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of overall ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

In the DESTINY-Breast03 trial, Enhertu (trastuzumab deruxtecan) reduced the risk of disease progression or death compared to Kadcyla (trastuzumab emtansine) by 72% in patients with HER2-positive ...

On Jan. 27, the Food and Drug Administration (FDA) granted approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for patients with unresectable or metastatic HR-positive, HER2-low or -ultralow breast ...

Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...

The results – simultaneously published in the journal Nature Medicine – also reveal an objective response rate (ORR) of 62.7% with Enhertu (trastuzumab deruxtecan), of which 9.5% were complete ...

Enhertu’s parts and active ingredients are: An antibody (with the ingredient fam-trastuzumab): This part ... Chemotherapy (with the ingredient deruxtecan-nxki): This part of the drug hinders ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

The safety profile of the novel antibody-drug conjugate was "manageable" and comparable to that of a similar drug, trastuzumab deruxtecan, researchers said. If approved, trastuzumab rezetecan ...

Photograph: Kind courtesy Thirdman/Pexels.com With the rising incidence of cancer in India, AstraZeneca India's breast cancer medicine trastuzumab deruxtecan (sold under the brand name Enhertu ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of ...